These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37191233)

  • 1. High concentration formulation developability approaches and considerations.
    Zarzar J; Khan T; Bhagawati M; Weiche B; Sydow-Andersen J; Alavattam S
    MAbs; 2023; 15(1):2211185. PubMed ID: 37191233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Screening Tools Used in High-Concentration Protein Formulation Development.
    Hofmann M; Gieseler H
    J Pharm Sci; 2018 Mar; 107(3):772-777. PubMed ID: 29102552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
    Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
    MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Intercompany Perspective on Practical Experiences of Predicting, Optimizing and Analyzing High Concentration Biologic Therapeutic Formulations.
    Desai PG; Garidel P; Gbormittah FO; Kamen DE; Mills BJ; Narasimhan CN; Singh S; Stokes ESE; Walsh ER
    J Pharm Sci; 2023 Feb; 112(2):359-369. PubMed ID: 36442683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-criteria manufacturability indices for ranking high-concentration monoclonal antibody formulations.
    Yang Y; Velayudhan A; Thornhill NF; Farid SS
    Biotechnol Bioeng; 2017 Sep; 114(9):2043-2056. PubMed ID: 28464235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools.
    Shan L; Mody N; Sormani P; Rosenthal KL; Damschroder MM; Esfandiary R
    Mol Pharm; 2018 Dec; 15(12):5697-5710. PubMed ID: 30395473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Stability of Therapeutic Proteins.
    Schuster J; Koulov A; Mahler HC; Detampel P; Huwyler J; Singh S; Mathaes R
    Pharm Res; 2020 Jan; 37(2):23. PubMed ID: 31900680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric formulation development - Challenges of today and strategies for tomorrow: Summary report from M-CERSI workshop 2019.
    Tan DCT; Khong YM; Mount S; Galella E; Mitra B; Charlton S; Kuhli M; Ternik R; Walsh J; Rajapakshe A; Thompson K; Mehrotra S; Santangelo M; Liu J; Dixit T; Schaufelberger D; Jamzad S; Klein S; Hoag SW; Wang J; Fletcher EP; Khurana M; Alexander J; Radden E; Sood R; Selen A
    Eur J Pharm Biopharm; 2021 Jul; 164():54-65. PubMed ID: 33878432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultradilute Measurements of Self-Association for the Identification of Antibodies with Favorable High-Concentration Solution Properties.
    Starr CG; Makowski EK; Wu L; Berg B; Kingsbury JS; Gokarn YR; Tessier PM
    Mol Pharm; 2021 Jul; 18(7):2744-2753. PubMed ID: 34105965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ongoing Challenges to Develop High Concentration Monoclonal Antibody-based Formulations for Subcutaneous Administration: Quo Vadis?
    Jiskoot W; Hawe A; Menzen T; Volkin DB; Crommelin DJA
    J Pharm Sci; 2022 Apr; 111(4):861-867. PubMed ID: 34813800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide Optimization at the Drug Discovery-Development Interface: Tailoring of Physicochemical Properties Toward Specific Formulation Requirements.
    Evers A; Pfeiffer-Marek S; Bossart M; Heubel C; Stock U; Tiwari G; Gebauer B; Elshorst B; Pfenninger A; Lukasczyk U; Hessler G; Kamm W; Wagner M
    J Pharm Sci; 2019 Apr; 108(4):1404-1414. PubMed ID: 30528197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AF4 and PEG Precipitation as Predictive Assays for Antibody Self-Association.
    Condado-Morales I; Sokolova V; Wahlund PO; Heding KE; Auclair S; Kingsbury JS; Arosio P; Lorenzen N
    Mol Pharm; 2023 Feb; 20(2):1323-1330. PubMed ID: 36668814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of Primary Drying in Lyophilization During Early-Phase Drug Development Using a Definitive Screening Design With Formulation and Process Factors.
    Goldman JM; More HT; Yee O; Borgeson E; Remy B; Rowe J; Sadineni V
    J Pharm Sci; 2018 Oct; 107(10):2592-2600. PubMed ID: 29890172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Product-Specific Impact of Viscosity Modulating Formulation Excipients During Ultra-High Concentration Biotherapeutics Drug Product Development.
    Rodrigues D; Tanenbaum LM; Thirumangalathu R; Somani S; Zhang K; Kumar V; Amin K; Thakkar SV
    J Pharm Sci; 2021 Mar; 110(3):1077-1082. PubMed ID: 33340533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for high-concentration drug substance manufacturing to facilitate subcutaneous administration: A review.
    Holstein M; Hung J; Feroz H; Ranjan S; Du C; Ghose S; Li ZJ
    Biotechnol Bioeng; 2020 Nov; 117(11):3591-3606. PubMed ID: 32687221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput viscosity measurement using capillary electrophoresis instrumentation and its application to protein formulation.
    Allmendinger A; Dieu LH; Fischer S; Mueller R; Mahler HC; Huwyler J
    J Pharm Biomed Anal; 2014 Oct; 99():51-8. PubMed ID: 25077704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High concentration biotherapeutic formulation and ultrafiltration: Part 1 pressure limits.
    Lutz H; Arias J; Zou Y
    Biotechnol Prog; 2017 Jan; 33(1):113-124. PubMed ID: 27452237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicochemical Rules for Identifying Monoclonal Antibodies with Drug-like Specificity.
    Zhang Y; Wu L; Gupta P; Desai AA; Smith MD; Rabia LA; Ludwig SD; Tessier PM
    Mol Pharm; 2020 Jul; 17(7):2555-2569. PubMed ID: 32453957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation workshop 2019.
    Khong YM; Liu J; Cook J; Purohit V; Thompson K; Mehrotra S; Cheung SYA; Hay JL; Fletcher EP; Wang J; Sachs HC; Zhu H; Siddiqui A; Cunningham L; Selen A
    Eur J Pharm Biopharm; 2021 Jul; 164():66-74. PubMed ID: 33878434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.